Logo

MorphoSys Antibodies by Design and JPT Peptide Technologies to Co-Market Products and Services

Apr 18, 2005

NEW YORK, April 18 (GenomeWeb News) - MorphoSys' Antibodies by Design division and JPT Peptide Technologies of Germany will co-market their antibody and peptide products and services, the companies said today.

 

Under the agreement, Antibodies by Design, of Martinsried, and JPT, a subsidiary of Berlin-based Jerini, will offer each other's products and services to customers worldwide, except for Japan.

 

Antibodies by Design develops monoclonal antibodies, while JPT offer complementary peptide-based services and products.

Breaking News
The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.